ArticleWorm2013
O-GlcNAc cycling shows neuroprotective potential in C. elegans models of neurodegenerative disease.
Article in Worm, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- O-GlcNAc transferase plays a non-catalytic role in C. elegans male fertility.PLoS genetics · 2022Article
- Intellectual disability-associated disruption of O-GlcNAc cycling impairs habituation learning in Drosophila.PLoS genetics · 2022Article
- Modeling Alzheimer's Disease inBiomedicines · 2022Review
- Article
- Article
- Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatmentJCI insight · 2020Article
- Modulation of O-GlcNAcylation Regulates Autophagy in Cortical Astrocytes.Oxidative medicine and cellular longevity · 2019Article
- Article
- Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits.Frontiers in neuroscience · 2018Review
- Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.Journal of neurochemistry · 2018Review
- Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease.Biology direct · 2016Review
- Tau physiology and pathomechanisms in frontotemporal lobar degeneration.Journal of neurochemistry · 2016Review
- Conditional knock-out reveals a requirement for O-linked N-Acetylglucosaminase (O-GlcNAcase) in metabolic homeostasis.The Journal of biological chemistry · 2015Article
- Multiple tissue-specific roles for the O-GlcNAc post-translational modification in the induction of and complications arising from type II diabetes.The Journal of biological chemistry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
C. elegans has proven to be an excellent organism in which to model human neurodegenerative disease.(1) (-) (7) The worm's simple nervous system, lineage, and neural maps, easily scored movement phenotypes, and robust forward and reverse genetics make it optimal for studying age-dependent processes on a reasonable time scale. A popular approach has been the introduction of transgenes expressing GFP-tagged proteotoxic human proteins into neurons leading to visible aggregation or movement phenotypes.(2) (,) (4) (,) (6) (,) (8) (-) (13) In addition, the maintenance of proteostasis networks has been extensively studied using the power of worm genetics.(8) (-) (13) These networks include genes involved in insulin-like signaling, the heat shock response, the response to hypoxia, and mTOR and AMPK pathways linked to aging.(14) Another pathway with suggestive links to neurodegeneration is the O-GlcNAc cycling pathway, a nutrient-dependent post-translational modification known to be altered in brains from patients with Alzheimer disease.(15) (-) (19) In this commentary, we summarize our recent findings showing that viable mutants of O-GlcNAc cycling in C. elegans dramatically alter the neurotoxicity of four distinct C. elegans models of neurodegenerative disease.(7) Mutants in O-GlcNAc cycling alter the toxicity of mutant tau, polyglutamine expansion reporters, and amyloid β-peptide. The findings further suggest that O-GlcNAc cycling acts at many steps in the lifecycle of aggregation-prone targets. The C. elegans system is likely to continue to provide insights into this complex problem. The involvement of O-GlcNAc cycling in the maintenance of proteostasis raises the possibility of targeting the enzymes catalyzing this critical post-translational modification for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.